Page 101 - Read Online

Page 16 of 16 D’Amico et al. J Cancer Metastasis Treat 2021;7:3 I http://dx.doi.org/10.20517/2394-4722.2020.93

64. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel
sequencing. Proc Natl Acad Sci U S A 2011;108:9530-5.
65. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of
plasma DNA. Sci Transl Med 2012;4:136ra68.
66. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat
Med 2014;20:548-54.
67. Kim AS, Bartley AN, Bridge JA, et al. Comparison of laboratory-developed tests and FDA-approved assays for BRAF, EGFR, and
KRAS testing. JAMA Oncol 2018;4:838-41.
68. Gorges TM, Penkalla N, Schalk T, et al. Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a
Novel In vivo Device for Capturing Circulating Tumor Cells. Clin Cancer Res 2016;22:2197-206.
69. Hyun KA, Koo GB, Han H, et al. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in
circulating tumor cells from metastatic breast cancer. Oncotarget 2016;7:24677-87.
70. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.
Science 2013;339:580-4.
71. Raimondi C, Nicolazzo C, Gradilone A. Circulating tumor cells isolation: the “post-EpCAM era”. Chin J Cancer Res 2015;27:461-70.
72. Loeian MS, Mehdi Aghaei S, Farhadi F, et al. Liquid biopsy using the nanotube-CTC-chip: capture of invasive CTCs with high purity
using preferential adherence in breast cancer patients. Lab Chip 2019;19:1899-915.
73. Bidard FC, Belin L, Delaloge S, et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast
cancer: 70-month analysis of the REMAGUS02 study. Int J Breast Cancer 2013;2013:130470.
74. Riethdorf S, Müller V, Loibl S, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant
“Geparquattro” trial. Clin Cancer Res 2017;23:5384-93.
75. Goodman CR, Seagle BL, Friedl TWP, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-
stage breast cancer. JAMA Oncol 2018;4:e180163.
76. Sparano J, O’Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast
cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018;4:1700-6.
77. Ignatiadis M, Litière S, Rothe F, et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor
cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Ann Oncol 2018;29:1777-83.
78. Kasimir-Bauer S, Bittner AK, König L, et al. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of
disseminated and circulating tumor cells before and after therapy. Breast Cancer Res 2016;18:20.